AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$KNSA

Megna Michael R sold $369K of KNSA

Megna Michael R (CHIEF ACCOUNTING OFFICER) sold 4,600 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at $80.30 ($0.37M total) on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Megna Michael R
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KNSA
Neutral
high confidence
Mentioned
$KNSA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KNSANeutralLow
01

Why it matters

The transaction is a standard 10b5‑1 sale with limited market impact.

02

Market read

Minor insider sell; unlikely to move the stock significantly.

03

What to watch

Potential upcoming dilution or strategic changes not disclosed.

Relevance 3/10Novelty 4/10Timing: today

Background

SEC Form 4 filing by Kiniksa Pharmaceuticals' chief accounting officer showing a routine insider sale under $1M.

Company-level read

Ticker impact

$KNSANeutralHigh confidence
Context

Form 4 disclosed a 4,600‑share sale by CAO Michael R. Megna for $369,380, reducing his holdings to 29,062 shares.

Expected impact

minimal, potential slight dip

Evidence & confidence

Sale size is small relative to market cap and executed via a pre‑arranged 10b5‑1 plan, indicating no new negative information.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market impact negligible.

Global

None

Counterpoint

What could challenge this read

If insider confidence is low, the sell could signal upcoming weakness.

Key entities

  • company
    Kiniksa Pharmaceuticals International, plc

    Biopharma company listed on Nasdaq under ticker KNSA.

  • person
    Michael R. Megna

    Chief Accounting Officer of KNSA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KNSA insider trading history →

Related articles

JUL 29
$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

rttnews.com7 min
JUL 28
$KNSAHighAI 9/10

Kiniksa Pharmaceuticals Shares Surge 21% on Strong ARCALYST Sales and Raised 2026 Guidance

Kiniksa Pharmaceuticals International plc shares rose about 21% on Nasdaq after its Q2 results for ARCALYST (rilonacept) beat expectations and it raised 2026 guidance. Net product revenue was $243.6M, about 55% higher year over year. 2026 guidance increased to $980M-$995M from $930M-$945M. Kiniksa also reported Q2 net income of $25.4M and $525.9M cash, and is enrolling PASTORALE for KPL-387.

ibtimes.com.au7 min
JUL 28
$KNSAMed

Kiniksa Pharmaceuticals International, plc (KNSA): Results of Operations and Financial Condition

Kiniksa Pharmaceuticals International, plc (KNSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 knsa-20260728xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ ​ Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –

SEC EDGAR 8-K4 min